ImmunityBio Q3 product revenue $6.0M, net loss narrows; ANKTIVA J-code set for Jan 2025

ImmunityBio, Inc.

2024-Q3 EPS reported -$0.53 revenue$7,193,000

Net product revenue of $6.0M from ANKTIVA launch in Q3, up from $1.0M in Q2; diluted EPS -$0.14 vs -$0.19 YoY.
Permanent J-code for ANKTIVA issued, effective Jan 1, 2025; medical coverage for over 200M lives secured.
MAA submitted to UK MHRA for ANKTIVA; EU submission planned in Q4 2024, covering 30 countries.
Cash and marketable securities $130.4M as of Sept 30; net loss attributable to stockholders -$85.7M vs -$95.6M YoY.
ANKTIVA shelf life extended to 3 years; over 125,000 doses available for market and trials.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.